RxDoctor Payments Data

Jason Moellinger, MD

Urology · Homewood, ALNPI 1629165535

Payments from drug & device makers

$5,137in general payments, 2019–2025

Across 188 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$2K
  • Sumitomo Pharma America, Inc.$1K
  • Astellas Pharma US Inc$422
  • Urovant Sciences Inc$287
  • AbbVie$259
  • Pfizer$153
  • plus $1K from 35 others

What the payments were for

  • Travel & lodging$96719%
  • Food & beverage$3,82374%
  • Education$3477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,137 in reported general payments places this provider in the 55th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$226,722
Medicare patients
644
Services billed
5,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron309$175,798
GemtesaVibegron112$84,202
Tamsulosin Hcl1,208$16,040
Dutasteride224$5,774
Silodosin53$4,684
Mirabegron ErMirabegron13$3,988
NitrofurantoinNitrofurantoin Macrocrystal141$3,551
Finasteride246$2,961
Testosterone16$2,307
Solifenacin Succinate64$2,295
Estradiol26$1,879
Potassium Citrate ErPotassium Citrate27$1,731
Oxybutynin Chloride ErOxybutynin Chloride106$1,602
Alfuzosin Hcl ErAlfuzosin Hcl81$1,489
Tadalafil18$1,468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$422$175,798309 claims
Sumitomo Pharma America, Inc.Gemtesa$1,108$84,202112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 179 urology providers in Alabama.

Other urology in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →